Figure 1.

Administration of trial medication (upper half of the diagram) and definition of treatment periods for safety analyses (lower half of the diagram). Dabigatran etexilate was always given in the morning at 08.00 h. Rifampicin was always administered in the evening at 20.00 h, with the last dose given 12 h before the dabigatran etexilate test treatment on day 9. D150, dabigatran etexilate 150 mg; R600, rifampicin 600 mg; D+R, dabigatran etexilate + rifampicin; P2, P3, period 2, period 3.